Glaxo chief: Our drugs do not work on most patients

GSK and it's filthy production facility in Canada kept on providing flu vaccine for human  beings in Canada and the US.-Salmonella with your flu vaccine, Canada? What other dirt has been dished up by GSK in recent years?Found an older interesting news article- Our drugs don't work on most people You will notice that hasn't stopped GSK from manufacturing acknowledged useless drugs at a great profit.

Allen Roses, worldwide vice-president of genetics at GlaxoSmithKline (GSK), said fewer than half of the patients prescribed some of the most expensive drugs actually derived any benefit from them.It is an open secret within the drugs industry that most of its products are ineffective in most patients but this is the first time that such a senior drugs boss has gone public. His comments come days after it emerged that the NHS drugs bill has soared by nearly 50 per cent in three years, rising by £2.3bn a year to an annual cost to the taxpayer of £7.2bn. GSK announced last week that it had 20 or more new drugs under development that could each earn the company up to $1bn (£600m) a year."The vast majority of drugs - more than 90 per cent - only work in 30 or 50 per cent of the people," Dr Roses said. "I wouldn't say that most drugs don't work. I would say that most drugs work in 30 to 50 per cent of people. Drugs out there on the market work, but they don't work in everybody."

Of course he is promoting genetically geared drugs as the panacea to this problem, but, that hasn't panned out either.

"Roses is a smart guy and what he is saying will surprise the public but not his colleagues," said one industry scientist.

 The figures cited below are likely grossly exaggerated also,but, still they are damning enoughTherapeutic area: drug efficacy rate in per cent

  • Alzheimer's: 30
  • Analgesics (Cox-2): 80
  • Asthma: 60
  • Cardiac Arrythmias: 60
  • Depression (SSRI): 62
  • Diabetes: 57
  • Hepatits C (HCV): 47
  • Incontinence: 40
  • Migraine (acute): 52
  • Migraine (prophylaxis)50
  • Oncology: 25
  • Rheumatoid arthritis50
  • Schizophrenia: 60

 I am sure GSK is not the only drug manufacturer with similarily dismal stats